- Home
- ORKA
as 11-21-2025 3:37pm EST
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 1.2B | IPO Year: | N/A |
| Target Price: | $45.22 | AVG Volume (30 days): | 410.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.49 - $29.98 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oruka Therapeutics Inc. Common Stock News
ORKA Breaking Stock News: Dive into ORKA Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA)
Zacks
24 days ago
Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know
GlobeNewswire
24 days ago
Oruka Therapeutics to Present at Multiple November Investor Conferences
MT Newswires
a month ago
Guggenheim Initiates Oruka Therapeutics at Buy With $60 Price Target
Insider Monkey
6 months ago
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
GlobeNewswire
6 months ago
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
6 months ago
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
GlobeNewswire
6 months ago
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Compare ORKA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORKA Oruka Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.